Insilico to present at the 2019 Undoing Aging Conference
Credit: Insilico Medicine
Tuesday, March 12, 2019 – Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery and productive longevity at the 2019 Undoing Aging Conference in Berlin, March 28-30.
Aging is a complex process that has been observed in all biological systems at every level of organization. Some anti-aging interventions have demonstrated life-extending effects in model organisms. Although very good progress has been made in the area, the translation of these interventions in human clinical practice remains limited due to the absence of comprehensive aging biomarkers.
Since 2015, Insilico Medicine’s deep learning team has developed multiple predictors of human biological age using a variety of data types including blood biochemistry, imaging, and microbiome data. Some of the most valuable aging clocks were developed using the gene expression data as these clocks may be used to identify the relevant biological targets for interventions.
The presentation will cover the application of aging clocks for generation of synthetic transcriptomic data, demonstrating the applications of this technique to the generation of millions of diverse gene expression profiles and identification of the novel biological targets.
“We are happy to present our latest research at the 2019 Undoing Aging Conference, which gathers the leading longevity leaders. The topic of Biomarkers of Aging is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area”, said Daniil Polykovskiy, Senior Research Scientist at Insilico Medicine, Inc.
Undoing Aging 2019 will focus on bringing together scientists and startups from around the globe in their respective fields, who are leading the charge in maintaining and restoring full health in old age. Speakers include leading researchers from around the world focused on topics including stem cells, senescent cells, immunotherapies, biomarkers, and drug discovery. Undoing Aging 2019 is not only open to the scientific community but also welcomes all members of the broader rejuvenation movement and interested media.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
For further information, images or interviews, please contact:
Contact: Polina Firsanova
Official website of the conference:
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/